

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
27 January 2022 (27.01.2022)



(10) International Publication Number  
**WO 2022/018171 A1**

- (51) **International Patent Classification:**  
*A61K 48/00* (2006.01) *C12N 15/86* (2006.01)
- (21) **International Application Number:**  
PCT/EP2021/070455
- (22) **International Filing Date:**  
21 July 2021 (21.07.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/055,775 23 July 2020 (23.07.2020) US
- (71) **Applicant:** UCL BUSINESS LTD [GB/GB]; The Network Building, 97 Tottenham Court Road, London W1T 4TP (GB).
- (72) **Inventors:** WADDINGTON, Simon Nicholas; 4c Burlington Gardens, Acton, London W3 6BA (GB). KAR-DA, Rajvinder; 711 Bath Road, Taplow, Maidenhead Berkshire SL60PB (GB). HERZOG, Christopher Dean; c/o Rocket Pharmaceuticals, Ltd., The Empire State Bldg., 350 Fifth Ave., Ste. 7530, New York 10118 (US). NG, Joanne; 122 County Hall South Block, 1B Belvedere Road, London SE1 7GD (GB). SACRAMENTO, Chester; c/o Rocket Pharmaceuticals, Ltd., The Empire State Bldg., 350 Fifth Ave., Ste. 7530, New York 10118 (US). SCHORGE, Stephanie; GFF 104 Axminster Road, London N7 6BS (GB). RICKS, David; c/o Rocket Pharmaceuticals, Ltd., The Empire State Bldg., 350 Fifth Ave., Ste. 7530, New York 10118 (GB).
- (74) **Agent:** COOLEY (UK) LLP; 22 Bishopsgate, London Greater London EC2N 4BQ (GB).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** GENE THERAPY VECTOR FOR eF1A2 AND USES THEREOF




FIG. 1

(57) **Abstract:** Provided herein is a gene therapy for neurological disease using a recombinant adeno-associated virus (rAAV) virion as a vector to express an eF1A2 protein or functional variant thereof. The rAAV virion may use a neuron-specific promoter, e.g., a human synapsin 1 (hSYN) promoter. The capsid may be an AAV9 capsid or functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intracerebrally and/or intravenously of the rAAV virion, and other compositions and methods.

WO 2022/018171 A1